natgillin/translations-raw huggingface dataset:
(optional) most recent training course of at least three hours on any aspect of computer use (within the last three months; between three months and one year ago; between one and three years ago; more than three years ago; never taken a course).
(neobvezno) zadnji tečaj za katero koli področje uporabe računalnika, ki je trajal vsaj tri ure (v zadnjih treh mesecih; pred več kot tremi meseci do pred enim letom; pred več kot enim letom do pred tremi leti; pred več kot tremi leti; tečaja ni nikoli opravljal).
Characteristics to be collected for individuals having ever used the Internet:
Karakteristike, ki se zberejo za posameznike, ki so že uporabljali internet:
Internet skills for using peer-to-peer file sharing for exchanging movies, music, etc.,
internetno znanje za medsebojno izmenjavo filmov, glasbe itd.,
Barriers to the use of ICT and the Internet
Ovire pri uporabi IKT in interneta
Characteristics to be collected for households without access to the Internet at home:
Karakteristike, ki se zberejo za gospodinjstva brez dostopa do interneta doma:
reason for not having access to the Internet at home: have access to Internet elsewhere,
razlog za nedostop do interneta doma: dostop do interneta je mogoč od kje drugje,
reason for not having access to the Internet at home: do not want Internet (because content harmful, etc.),
razlog za nedostop do interneta doma: interneta ne želi (zaradi škodljivih vsebin itd.),
reason for not having access to the Internet at home: do not need Internet (because not useful, not interesting, etc.),
razlog za nedostop do interneta doma: interneta ne potrebuje (zaradi nekoristnosti, nezanimivosti itd.),
reason for not having access to the Internet at home: equipment costs too high,
razlog za nedostop do interneta doma: previsoki stroški opreme,
reason for not having access to the Internet at home: access costs too high (telephone, etc.),
razlog za nedostop do interneta doma: previsoki stroški dostopa (telefon itd.),
reason for not having access to the Internet at home: lack of skills,
razlog za nedostop do interneta doma: pomanjkanje znanja,
reason for not having access to the Internet at home: privacy or security concerns,
razlog za nedostop do interneta doma: skrbi v zvezi z zasebnostjo ali varnostjo,
reason for not having access to the Internet at home: physical disability,
razlog za nedostop do interneta doma: invalidnost,
reason for not having access to the Internet at home: none of the above, but other.
razlog za nedostop do interneta doma: nič od naštetega, vendar nekaj drugega.
The statistical units to be represented for the characteristics listed in heading 1(b) of this Annex that relate to households are households with at least one member in the age group 16 to 74.
Statistične enote, ki morajo biti zastopane pri karakteristikah iz naslova 1(b) te priloge, ki se nanašajo na gospodinjstva, so gospodinjstva z vsaj enim članom v starostni skupini 16 do 74 let.
The statistical units to be represented for the characteristics listed in heading 1(b) of this Annex that relate to individuals are individuals aged 16 to 74.
Statistične enote, ki morajo biti zastopane pri karakteristikah iz naslova 1(b) te priloge, ki se nanašajo na posameznike, so posamezniki v starostni skupini 16 do 74 let.
The geographic scope comprises households and/or individuals living in any part of the territory of the Member State.
Geografsko so zajeta gospodinjstva in/ali posamezniki, ki živijo na katerem koli delu ozemlja države članice.
The main reference period for the statistics to be collected is the first quarter of 2010.
Glavno referenčno obdobje, v katerem se zbirajo statistični podatki, je prvo četrtletje leta 2010.
For the subjects and their characteristics listed in heading 1(b) of this Annex that relate to households, the following background characteristics are to be collected:
Za področja in njihove karakteristike iz naslova 1(b) te priloge, ki se nanašajo na gospodinjstva, se zberejo naslednje osnovne karakteristike:
degree of urbanisation: living in densely populated areas; living in intermediate populated areas; living in sparsely populated areas,
stopnja urbanizacije: živi na gosto poseljenem območju; živi na srednje poseljenem območju; živi na redko poseljenem območju,
type of household: number of members in the household (to be collected separately: number of children under 16).
vrsta gospodinjstva: število članov gospodinjstva (ločeno se zbira za: število otrok v starosti manj kot 16 let).
For the subjects and their characteristics listed in heading 1(b) of this Annex that relate to individuals, the following background characteristics are to be collected:
Za področja in njihove karakteristike iz naslova 1(b) te priloge, ki se nanašajo na posameznike, se zberejo naslednje osnovne karakteristike:
age (to be collected as a value or using age groups): under 16 (optional); 16 to 24; 25 to 34; 35 to 44; 45 to 54; 55 to 64; 65 to 74; over 74 (optional),
starost (zbira se kot vrednost ali ob upoštevanju starostne skupine): pod 16 let (neobvezno); 16 do 24; 25 do 34; 35 do 44; 45 do 54; 55 do 64; 65 do 74; nad 74 let (neobvezno),
highest completed level of education according to the International Standard Classification of Education (ISCED 97): low (ISCED 0, 1 or 2); middle (ISCED 3 or 4); high (ISCED 5 or 6),
najvišja dokončana stopnja izobrazbe v skladu z Mednarodno standardno klasifikacijo izobraževanja (ISCED 97): nižja (ISCED 0, 1 ali 2); srednja (ISCED 3 ali 4); visoka (ISCED 5 ali 6),
employment situation: employee or self-employed, including family workers; unemployed; students not in the labour force; other not in the labour force,
zaposlenost: zaposleni ali samozaposleni, vključno z družinskimi delavci; brezposelni; študentje, ki niso na trgu dela; drugi, ki niso na trgu dela,
occupation according to the International Standard Classification of Occupations (ISCO-88): manual workers; non-manual workers; ICT workers, non-ICT workers.
poklic po standardih Mednarodne klasifikacije poklicev (ISCO-88): delavci, ki opravljajo fizična dela, delavci, ki ne opravljajo fizičnih del; delavci v IKT, delavci, ki niso zaposleni v IKT.
DEADLINES FOR TRANSMISSION OF RESULTS
ROKI ZA POŠILJANJE REZULTATOV
The quality report referred to in Article 7(4) of Regulation (EC) No 808/2004 must be forwarded to Eurostat by 5 November 2010.
Poročilo o kakovosti iz člena 7(4) Uredbe (ES) št. 808/2004 je treba poslati Eurostatu do 5. novembra 2010.
The aggregate data referred to in Article 6 of Regulation (EC) No 808/2004, where necessary flagged for confidentiality or unreliability, must be forwarded to Eurostat before 5 October 2010 or, for aggregate data on the subject ‘ICT investment and expenditure’, before 30 June 2011.
Zbrane podatke iz člena 6 Uredbe (ES) št. 808/2004, ki so po potrebi označeni kot zaupni ali nezanesljivi, je treba poslati Eurostatu do 5. oktobra 2010, zbrani podatki o „naložbi in stroških IKT“ pa do 30. junija 2011.
By that date, the dataset has to be finalised, validated and accepted.
Do tega datuma je treba podatkovne nize dokončno izoblikovati, potrditi in sprejeti.
The metadata referred to in Article 6 of Regulation (EC) No 808/2004 must be forwarded to Eurostat before 31 May 2010.
Metapodatke iz člena 6 Uredbe (ES) št. 808/2004 je treba poslati Eurostatu do 31. maja 2010.
The quality report referred to in Article 7(4) of Regulation (EC) No 808/2004 must be forwarded to Eurostat by 5 November 2010 or, for the subject ‘ICT investment and expenditure’, before 31 July 2011.
Poročilo o kakovosti iz člena 7(4) Uredbe (ES) št. 808/2004 je treba poslati Eurostatu do 5. novembra 2010, za „naložbo in stroške IKT“ pa do 31. julija 2011.
The aggregate data referred to in Article 6 of Regulation (EC) No 808/2004, where necessary flagged for confidentiality or unreliability, must be forwarded to Eurostat before 5 October 2010.
Zbrani podatki iz člena 6 Uredbe (ES) št. 808/2004, ki so po potrebi označeni kot zaupni ali nezanesljivi, se pošljejo Eurostatu do 5. oktobra 2010.
Commission Regulation (EC) No 1024/2009
Uredba Komisije (ES) št. 1024/2009
on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children’s development and health
o odobritvi in zavrnitvi odobritve zdravstvenih trditev na živilih, ki se nanašajo na zmanjšanje tveganja za nastanek bolezni ter na razvoj in zdravje otrok
The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as the Authority.
Nacionalni pristojni organ veljavne vloge posreduje Evropski agenciji za varnost hrane (v nadaljnjem besedilu: Agencija).
On 14 November 2008 the Commission and the Member States received two opinions on applications for health claim authorisation from the Authority.
Komisija in države članice so 14. novembra 2008 prejele dve mnenji Agencije o vlogah za odobritev zdravstvenih trditev.
On 10 December 2008, the Commission and the Member States received five opinions on applications for health claim authorisation from the Authority.
Komisija in države članice so 10. decembra 2008 prejele pet mnenj Agencije o vlogah za odobritev zdravstvenih trditev.
On 19 December 2008, the Commission and the Member States received nine opinions on applications for health claim authorisation from the Authority.
Komisija in države članice so 19. decembra 2008 prejele devet mnenj Agencije o vlogah za odobritev zdravstvenih trditev.
On 15 January 2009, the Commission and the Member States received one opinion on an application for health claim authorisation from the Authority.
Komisija in države članice so 15. januarja 2009 prejele mnenje Agencije o vlogi za odobritev zdravstvene trditve.
Meanwhile one application for health claim authorisation was subject to a previous decision.
Ena vloga za odobritev zdravstvene trditve je že bila obravnavana.
One opinion was related to an application for reduction of disease risk claim, as referred to in Article 14(1)(a) of Regulation (EC) No 1924/2006, and 15 opinions were related to applications for health claims referring to children’s development and health, as referred to in Article 14(1)(b) of Regulation (EC) No 1924/2006.
Eno mnenje se je nanašalo na vlogo za zdravstveno trditev za zmanjšanje tveganja za nastanek bolezni, kakor je opredeljeno v členu 14(1)(a) Uredbe (ES) št. 1924/2006, 15 mnenj pa se je nanašalo na vloge za zdravstvene trditve v zvezi z razvojem in zdravjem otrok, kakor je opredeljeno v členu 14(1)(b) Uredbe (ES) št. 1924/2006.
Following an application from Leaf Int and Leaf Holland and Leaf Suomi Oy submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of xylitol chewing gum/pastilles on the risk of tooth decay (Question No EFSA-Q-2008-321) [2].
Družba LEAF Int and Leaf Holland and Leaf Suomi Oy je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi žvečilnih gumijev/pastil s ksilitolom na tveganje nastanka zobne gnilobe (vprašanje št. EFSA-Q-2008-321) [2].
The claim proposed by the applicant was worded as follows: ‘Xylitol chewing gum/pastilles reduces the risk of caries’.
Vlagatelj je predlagal naslednjo trditev: „Žvečilni gumiji/pastile s ksilitolom zmanjšujejo tveganje za nastanek kariesa.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship was established between the consumption of chewing gum sweetened with 100 % xylitol and the claimed effect.
Agencija je na podlagi predloženih podatkov ugotovila, da je vzročno-posledična povezava med uživanjem žvečilnih gumijev, sladkanih s 100-odstotnim ksilitolom, in navedeno trditvijo utemeljena.
However, it concluded that a cause and effect relationship had not been established between the consumption of pastilles sweetened with at least 56 % xylitol and the claimed effect.
Hkrati je ugotovila, da vzročno-posledična povezava med uživanjem pastil, sladkanih z najmanj 56-odstotnim ksilitolom, in navedeno trditvijo ni utemeljena.
Subject to a revised wording, the claim should be considered as complying with the requirements of Regulation (EC) No 1924/2006 and in particular Article 14(1)(a) thereof, and it should be included in the Community list of permitted claims.
Trditev je ob spremembi besedila treba šteti za skladno z zahtevami iz Uredbe (ES) št. 1924/2006 in zlasti iz člena 14(1)(a) Uredbe ter jo uvrstiti na seznam dovoljenih trditev Skupnosti.
Following an application from Danone SA submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of dairy fresh cheese with significant amounts of calcium, vitamin D, phosphorus and protein on bone growth (Question No EFSA-Q-2008-217) [3].
Družba Danone S.A. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi mlečnega svežega sira z visoko vsebnostjo kalcija, vitamina D, fosforja in beljakovin na rast kosti (vprašanje št. EFSA-Q-2008-217) [3].
The claim proposed by the applicant was worded as follows: ‘Dairy fresh cheese contains calcium, vitamin D, phosphorus and protein, nutrients that contribute to healthy bone growth’.
Vlagatelj je predlagal naslednjo trditev: „Mlečni sveži sir vsebuje kalcij, vitamin D, fosfor in beljakovine, tj. hranila, ki prispevajo k zdravi rasti kosti“.
On the basis of the data presented, the Authority concluded that a cause and effect relationship was established between the consumption of calcium, vitamin D, phosphorus and protein and the claimed effect.
Agencija je na podlagi predloženih podatkov ugotovila, da je vzročno-posledična povezava med uživanjem kalcija, vitamina D, fosforja in beljakovin ter navedeno trditvijo utemeljena.
Subject to a revised wording and taking into account that health claims for the same claimed effect are authorised for calcium, vitamin D and protein, the claim for phosphorus should be considered as complying with the requirements of Regulation (EC) No 1924/2006, and it should be included in the Community list of permitted claims.
Trditev je ob spremembi besedila in ob upoštevanju, da so zdravstvene trditve za isti navedeni vpliv odobrene za kalcij, vitamin D in beljakovine, treba šteti za skladno z zahtevami iz Uredbe (ES) št. 1924/2006 ter jo uvrstiti na seznam dovoljenih trditev Skupnosti.
Article 16(4) of Regulation (EC) No 1924/2006 provides that an opinion in favour of authorising a health claim should include certain particulars.
Člen 16(4) Uredbe (ES) št. 1924/2006 določa, da mora mnenje, ki podpira odobritev znanstvene trditve, vsebovati nekatere podatke.
Accordingly, those particulars should be set out in the Annex I to the present Regulation as regards the two authorised claims and include, as the case may be, the revised wording of the claim, specific conditions of use of the claim, and, where applicable, conditions or restrictions of use of the food and/or an additional statement or warning, in accordance with the rules laid down in Regulation (EC) No 1924/2006 and in line with the opinions of the Authority.
Navedeni podatki v zvezi z dvema odobrenima trditvama morajo biti določeni v Prilogi I k tej uredbi ter vsebovati, odvisno od primera, spremenjeno besedilo trditve, posebne pogoje uporabe trditve in, kjer je to ustrezno, pogoje ali omejitve uporabe živila in/ali dodatno pojasnilo ali opozorilo v skladu s predpisi iz Uredbe (ES) št. 1924/2006 in mnenji Agencije.
One of the objectives of the Regulation (EC) No 1924/2006 is to ensure that health claims are truthful, clear and reliable and useful to the consumer, and that wording and presentation have to be taken into account in that respect; that therefore where the wording of claims has the same meaning for consumers as that of an authorised health claim as they demonstrate the same relationship that exists between a food category, a food or one of its constituents and health, included in Annex I to the present Regulation, they should be subject to the same conditions of use indicated therein.
Ker je eden od ciljev Uredbe (ES) št. 1924/2006 zagotoviti, da so zdravstvene trditve resnične, jasne, zanesljive in uporabne za potrošnika, je treba pri tem upoštevati besedilo in predstavitev trditve; kadar ima besedilo trditve za potrošnike enak pomen kot odobrena zdravstvena trditev iz Priloge I k tej uredbi, če predstavljata isto povezavo med kategorijo živila, živilom ali njegovo sestavino in zdravjem, je treba to trditev uporabljati pod istimi pogoji, ki so navedeni v navedeni prilogi.
Following an application from the Institute of Biotechnology, Sera and Vaccines Biomed SA, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactoral on the normal functioning of the alimentary tract (Question No EFSA-Q-2008-269) [4].
Družba Institute of Biotechnology, Sera and Vaccines Biomed S.A. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi LACTORAL na normalno delovanje prebavil (vprašanje št. EFSA-Q-2008-269) [4].
The claim proposed by the applicant was worded as follows: ‘Lactoral helps to bring back the normal functioning of the alimentary tract during its microflora disturbances (for example, in case of loose stools, after taking antibiotics, in case of intestinal disorders caused by enteric pathogens)’.
Vlagatelj je predlagal naslednjo trditev: „LACTORAL pomaga pri vzpostavitvi normalnega delovanja prebavil pri motnjah mikroflore (npr. pri driski, po uživanju antibiotikov, v primeru črevesnih bolezni)“.
On the basis of the data presented, the Authority concluded that the constituents of Lactoral are insufficiently characterised, and that a cause and effect relationship had not been established between the consumption of Lactoral and the claimed effect.
Agencija je na podlagi predloženih podatkov ugotovila, da sestavine LACTORAL niso zadovoljivo opredeljene ter da vzročno-posledična povezava med uživanjem LACTORAL in navedeno trditvijo ni utemeljena.
Following an application from the Institute of Biotechnology, Sera and Vaccines Biomed SA, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactoral on the improvement of the general immunity (Question No EFSA-Q-2008-477) [5].
Družba Institute of Biotechnology, Sera and Vaccines Biomed S.A. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi LACTORAL na krepitev splošne odpornosti (vprašanje št. EFSA-Q-2008-477) [5].
The claim proposed by the applicant was worded as follows: ‘Lactoral is recommended in order to improve the general immunity by maintaining the microbiological balance’.
Vlagatelj je predlagal naslednjo trditev: „LACTORAL je priporočljiv, ker z ohranjanjem mikrobiološkega ravnovesja krepi splošno odpornost“.
Following an application from the Institute of Biotechnology, Sera and Vaccines Biomed SA, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactoral on the building of the natural intestinal barrier (Question No EFSA-Q-2008-478) [6].
Družba Institute of Biotechnology, Sera and Vaccines Biomed S.A. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi LACTORAL na razvoj naravne črevesne pregrade (vprašanje št. EFSA-Q-2008-478) [6].
The claim proposed by the applicant was worded as follows: ‘Lactoral helps to protect the alimentary system against enteric pathogens because of strong antagonistic properties and helps to build the natural intestinal barrier’.
Vlagatelj je predlagal naslednjo trditev: „LACTORAL zaradi močnih antagonističnih lastnosti pomaga ščititi prebavni sistem pred črevesnimi povzročitelji bolezni in pomaga pri razvoju naravne črevesne pregrade“.
Following an application from the Institute of Biotechnology, Sera and Vaccines Biomed SA, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactoral on the maintenance of natural intestinal microflora during travel (Question No EFSA-Q-2008-479) [7].
Družba Institute of Biotechnology, Sera and Vaccines Biomed S.A. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi LACTORAL na ohranjanje naravne črevesne mikroflore med potovanjem (vprašanje št. EFSA-Q-2008-479) [7].
The claim proposed by the applicant was worded as follows: ‘Lactoral helps to maintain natural intestinal microflora during travel, changing the climatic zone or a diet, especially in poor hygiene conditions’.
Vlagatelj je predlagal naslednjo trditev: „LACTORAL pomaga ohranjati naravno črevesno mikrofloro med potovanjem, pri spremembi podnebja ali prehrane, zlasti v slabih higienskih razmerah“.
Following an application from the Institute of Biotechnology, Sera and Vaccines Biomed SA, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactoral on the living probiotic bacteria (Question No EFSA-Q-2008-480) [8].
Družba Institute of Biotechnology, Sera and Vaccines Biomed S.A. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi LACTORAL na žive probiotične bakterije (vprašanje št. EFSA-Q-2008-480) [8].
The claim proposed by the applicant was worded as follows: ‘Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infants’.
Vlagatelj je predlagal naslednjo trditev: „LACTORAL vsebuje žive probiotične bakterije z močno sposobnostjo črevesnega koloniziranja, izolirane pri zdravih, naravno hranjenih dojenčkih“.
On the basis of the data presented, the Authority concluded that the constituents of Lactoral are insufficiently characterised, and that the claimed effect had not been shown.
Agencija je na podlagi predloženih podatkov ugotovila, da sestavine LACTORAL niso zadovoljivo opredeljene in da navedena trditev ni bila dokazana.
Following an application from Potters Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Mumomega® on central nervous system development (Question No EFSA-Q-2008-328) [9].
Družba Potters Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Mumomega® na razvoj centralnega živčnega sistema (vprašanje št. EFSA-Q-2008-328) [9].
The claim proposed by the applicant was worded as follows: ‘Mumomega® provides the nourishments that support healthy central nervous system development’.
Vlagatelj je predlagal naslednjo trditev: „Mumomega® omogoča prehrano, ki spodbuja razvoj zdravega centralnega živčnega sistema“.
On the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of the food and the claimed effect.
Agencija je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem živila in navedeno trditvijo ni utemeljena.